Press "Enter" to skip to content

Gilead misses key goal in NASH liver disease trial, shares sink

Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company’s shares down 4.6 percent in after-hours trading.

Also Read:   Children's hospitals more likely to give recommended antibiotics for pneumonia